GLP-1

Women with polycystic ovarian syndrome ( PCOS ) have decreased growth hormone ( GH ), which can increase visceral adiposity...


The FDA ( U.S. Food and Drug Administration ) has approved Rybelsus ( Semaglutide ) oral tablets to improve control...


The aim of study was to investigate the efficacy, safety, and tolerability of oral Semaglutide ( Rybelsus ) added to...


Dulaglutide ( Trulicity ) significantly improves A1C ( average blood sugar concentration over two to three months ) when added...


New research presented at the annual meeting of the European Association for the Study of Diabetes ( EASD ) has...


The results from PIONEER 8, a phase 3a trial with oral Semaglutide ( Rybelsus ) for the treatment of adults with...


Findings from two phase 3a clinical trials for Semaglutide, an investigational glucagon-like peptide-1 ( GLP-1 ) analogue, were presented at...


Among patients recently hospitalized with heart failure and reduced left ventricular ejection fraction ( LVEF ), the use of the...


Several studies have shown that Exenatide protects against ischemia-reperfusion injury and improves cardiac function in patients with acute ST-segment elevation...


The results from SUSTAIN-1, the first phase 3a trial for Semaglutide, a new GLP-1 analogue administered once-weekly were presented. The...


Since protein ingestion is known to stimulate the secretion of glucagon-like peptide-1 ( GLP-1 ), researchers have hypothesised that enhancing...


A follow-up study of patients with Parkinson’s disease ( PD ) who participated in an earlier proof of concept clinical...


The incretin hormone, glucagon-like peptide-1 ( GLP-1 ), promotes myocardial glucose uptake and may improve myocardial tolerance to ischemia. Endogenous...


Combination treatment with a glucagon-like peptide-1 ( GLP-1 ) agonist and basal Insulin has been proposed as a treatment strategy...


A systematic review and meta-analysis has investigated the risk of pancreatitis associated with the use of incretin-based treatments in patients...


When patients with type 2 diabetes mellitus start their first injectable therapy, clinicians can choose between glucagon-like peptide-1 ( GLP-1...


The FDA ( Food and Drug Administration ) has approved Saxenda ( Liraglutide [ rDNA origin ] injection ) as...


The FDA ( Food and Drug Administration ) has approved the New Drug Application ( NDA ) for Saxenda (...


The efficacy and safety of Lixisenatide ( Lyxumia ), a once-daily prandial glucagon-like peptide-1 ( GLP-1 ) receptor agonist, in...


Positive top-line results of two additional phase III AWARD trials for Dulaglutide, an investigational, long-acting glucagon-like peptide 1 ( GLP-1...